Particle.news
Download on the App Store

Delani Diekmeier to Begin Week-Long IMAZA Cancer Therapy in Würzburg on Dec. 15

The nuclear-medicine treatment uses a radioactive agent to target tumor cells, requiring isolation during administration.

Overview

  • Parents Dennis and Dana Diekmeier say their 14-year-old daughter will be admitted in Würzburg for the IMAZA course starting Monday and monitored in isolation during the active phase.
  • During treatment, family members must remain behind glass as the injected radiotracer circulates, according to Dennis Diekmeier's account in interviews.
  • A late-November test dose showed visible tracer uptake, which the family described as a hopeful signal after earlier therapies failed.
  • Delani has faced a malignant kidney tumor that spread to her lungs, with multiple lung operations and several chemotherapies, and doctors cited in reports have estimated survival odds at about five percent.
  • The family plans a quiet Christmas and a possible trip to Austria if her condition allows, acknowledging that the medical response to this therapy will only be clear after the course.